Navigation Links
Novel method predicts impact of a covert anthrax release
Date:5/26/2009

A new statistical method that can estimate the origin and time of an aerosolized release of the pathogen causing anthrax, following detection of the first few cases has been developed by researchers from the Medical Research Council (MRC) Centre for Outbreak Analysis and Modelling at Imperial College London in collaboration with the Health Protection Agency's Microbial Risk Assessment group.

The method, described in an article published April 10 in the open-access journal PLoS Computational Biology, predicts where the most critically affected areas will be following the release of this highly pathogenic agent, which may enable preventative treatment of individuals at risk and protection from the disease.

Previously published methods can estimate the date and scale of anthrax release but not the source location or geographic extent of human exposure. The new method uses information about the first people infected, including when they started to experience symptoms of infection and where they live and work, combined with recent weather information, such as wind direction.

Dr Judith Legrand, lead author of the study from the MRC Centre for Outbreak Analysis and Modelling, said: "We have devised a new way to forecast the future course of a potential outbreak and the people and geographic areas likely to be worst affected."

Anthrax has the potential to cause a large number of deaths in the event of a covert, open air release. If such a release were to occur, it is critical for public health decision makers to evaluate its extent and the potential impact on the population and then to identify the people most at risk of infection as soon as possible.

Dr Judith Legrand added: "It is critical to treat people as soon as possible after exposure to anthrax. While forecasts based on small numbers of early cases are less reliable than those obtained later in an outbreak, we show that treating individuals based on early estimates is still likely to save lives overall."


'/>"/>

Contact: Dr. Judith Legrand
j.legrand@imperial.ac.uk
44-781-206-5019
Public Library of Science
Source:Eurekalert

Related biology technology :

1. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
2. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
3. New nanotube coating enables novel laser power meter
4. Nano-sandwich triggers novel electron behavior
5. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
6. Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tephas Proprietary Biomaterial
7. PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
8. Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union
9. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
10. Novel CU-Boulder technique shrinks size of nanotechnology circuitry
11. Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... host a Key Opinion Leader event to highlight new ... and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology ... event will be held in-person and via live webcast ... 9:00 AM PST at the Lotte New York Palace ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
Breaking Biology Technology:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
Breaking Biology News(10 mins):